Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 151 clinical trials
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL

This is a phase II interventional trial to evaluate the efficacy of ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph+ acute lymphoblastic leukemia. This combination has the potential to improve the depth of molecular responses after the induction phase of treatment. Patients who achieve a …

  • 0 views
  • 28 Jun, 2021
  • 7 locations
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Background Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective To …

combination chemotherapy
doxorubicin
vincristine
cyclophosphamide
acalabrutinib
  • 0 views
  • 09 May, 2021
  • 1 location
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Acute Lymphoblastic Leukemia

This phase I/II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating older patients with previously untreated acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent …

combination chemotherapy
vincristine
cyclophosphamide
monoclonal antibody therapy
cytarabine
  • 38 views
  • 11 May, 2021
  • 1 location
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

Philadelphia chromosome (BCR-ABL1, Ph) is the most common genetic abnormality in acute lymphoblastic leukemia (ALL) and an independent prognostic risk factor. With the increase of age, the incidence of patients over 60 years old can reach 50%, whose 5-year overall survival rate was less than 20%. With the application of …

philadelphia chromosome
tyrosine
prednisone
imatinib
benzene ring
  • 0 views
  • 25 Jan, 2021
  • 3 locations
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

Multiple myeloma (MM) is a common malignant hematology disease. The development of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) significantly improved the survival of MM patients. IMiDs have multiple effects in MM therapy. Except for direct cytotoxicity, IMiDs also play a variety of immune regulatory roles. Lenalidomide, a kind of …

multiple myeloma
lenalidomide
dexamethasone
proteasome inhibitor
bortezomib
  • 1 views
  • 23 Jan, 2021
  • 1 location
Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

To evaluate the feasibility of adding induction and maintenance Avelumab to the standard combination of R-CHOP in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)

ejection fraction
experimental drug
vincristine
cyclophosphamide
hodgkin's disease
  • 44 views
  • 22 Jan, 2021
  • 3 locations
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

The purpose of this study is to test the good and bad effects of the study drugs bortezomib and vorinostat when they are given in combination with chemotherapy commonly used to treat acute lymphoblastic leukemia (ALL) in infants. For example, adding these drugs could decrease the number of leukemia cells, …

hydroxyurea
vincristine
cyclophosphamide
vorinostat
asparaginase
  • 38 views
  • 09 May, 2021
  • 19 locations
High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

RATIONALE: Giving chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is given to prepare the bone marrow for the stem cell …

autologous hematopoietic stem cell transplant
t-cell lymphoma
doxorubicin
vincristine
cyclophosphamide
  • 36 views
  • 07 Nov, 2020
  • 1 location
Chemotherapy and G-CSF for Mobilization

This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while associated with fewer side effects in myeloma patients.

melphalan
granulocyte colony stimulating factor
colony stimulating factor
chemotherapy regimen
filgrastim
  • 4 views
  • 13 May, 2021
  • 1 location
Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Follicular lymphoma (FL) is a chronic indolent malignancy, where treatment with 6 cycles of bendamustine obinutuzumab (BO) is highly effective but at a cost of increased adverse events. Tumor specific DNA can be traced in blood and bone marrow of follicular lymphoma patients even after therapy, and when detected after …

follicular lymphoma
remission
bendamustine
obinutuzumab
  • 0 views
  • 28 Jun, 2021
  • 1 location